Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction?

Nature Reviews Cancer

Volumn 6, Issue 2, 2006, Pages 107-116

  Baylin, Stephen B ^a   Ohm, Joyce E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BETA CATENIN; FRIZZLED PROTEIN; HISTONE DEACETYLASE INHIBITOR; WNT PROTEIN;

CANCER CELL; CANCER GENETICS; CANCER PREVENTION; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENETIC CODE; HUMAN; KIDNEY CELL; MYELODYSPLASIA; NEPHROBLASTOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); SIGNAL TRANSDUCTION;

EID: 33644846509     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1799     Document Type: Review

References (123)

1. Hahn, W. C. et al. Creation of human tumour cells with defined genetic elements. Nature 400, 464-468 (1999).
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
3. Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812-816 (1993).
4. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
5. Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-763 (1997).
6. Jones, P. A. & Laird, P. W. Cancer epigenetics comes of age. Nature Genet. 21, 163-167 (1999).
7. Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143-153 (2004).
8. Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
9. Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415-428 (2002). Highlights how patterns of DNA methylation and chromatin structure are profoundly altered in neoplasia.
10. Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266 (2005).
11. Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391-400 (2005).
12. Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672-2681 (2002).
13. Lachner, M., O'Sullivan, R. J. & Jenuwein, T. An epigenetic road map for histone lysine methylation. J. Cell Sci. 116, 2117-2124 (2003). Reviews the known complexity of histone modifications including the methylation, acetylation and phosphorylation of histone residues.
14. Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41-45 (2000).
15. Fischle, W., Wang, Y. & Allis, C. D. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15, 172-183 (2003).
16. Hake, S. B., Xiao, A. & Allis, C. D. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 90, 761-769 (2004).
17. Kuzmichev, A. & Reinberg, D. Role of histone deacetylase complexes in the regulation of chromatin metabolism. Curr. Top. Microbiol. Immunol. 254, 35-58 (2001).
18. Ushijima, T. Detection and interpretation of altered methylation patterns in cancer cells. Nature Rev. Cancer 5, 223-231 (2005).
19. Akama, T. O. et al. Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. Cancer Res. 57, 3294-3299 (1997).
20. Costello, J. F. et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet. 24, 132-138 (2000).
21. Yu, L. et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genet. 37, 265-274 (2005).
22. Huang, T. H., Perry, M. R. & Laux, D. E. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8, 459-470 (1999).
23. Shi, H. et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63, 2164-2171 (2003).
24. Salem, C. E. et al. PAX6 methylation and ectopic expression in human tumor cells. Int. J. Cancer 87, 179-185 (2000).
25. Suzuki, H. et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet. 31, 141-149 (2002).
26. Yamashita, K. et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485-495 (2002).
27. Toyota, M. et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59, 2307-2312 (1999).
28. Herman, J. G. et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95, 6870-6875 (1998).
29. Bachman, K. E. et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3, 89-95 (2003).
30. ink4A alleles in neoplasia. Cancer Res. 58, 591-593 (1998).
31. Parsons, R. et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55, 5548-5550 (1995).
32. Morin, P. J. et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790 (1997).
33. Akiyama, Y. et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 23, 8429-8439 (2003).
34. Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genet. 36, 417-422 (2004). Demonstrates that epigenetic loss of SFRP function occurs early in colorectal cancer progression, and that restoration of SFRP function in colorectal cancer cells attenuates Wnt signalling, even in the presence of downstream mutations.
35. Rhee, I. et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552-556 (2002).
36. Bachman, K. E. et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59, 798-802 (1999).
37. Gao, X., Sedgwick, T., Shi, Y. B. & Evans, T. Distinct functions are implicated for the GATA-4, -5, and-6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol. Cell. Biol. 18, 2901-2911 (1998).
38. Al-azzeh, E. et al. Gastroprotective peptide trefoil factor family 2 gene is activated by upstream stimulating factor but not by c-Myc in gastrointestinal cancer cells. Gut 51, 685-690 (2002).
39. Bossenmeyer-Pourie, C. et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol. 157, 761-770 (2002).
40. Wright, N. A., Hoffmann, W., Otto, W. R., Rio, M. C. & Thim, L. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett. 408, 121-123 (1997).
41. Issa, J. P. CpG island methylator phenotype in cancer. Nature Rev. Cancer 4, 988-993 (2004). Reviews the concept of a DNA hyper-methylated phenotype.
42. Yamada, Y. et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl Acad. Sci. USA 102, 13580-13585 (2005).
43. Cui, H. et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753-1755 (2003).
44. Sakatani, T. et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307, 1976-1978 (2005).
45. Holm, T. M. et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8, 275-285 (2005).
46. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891-11896 (1998).
47. Nuovo, G. J., Plaia, T. W., Belinsky, S. A., Baylin, S. B. & Herman, J. G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA 96, 12754-12759 (1999).
48. INK4a in primary rat lung tumors. Mol. Cell. Biol. 17, 1366-1374 (1997).
49. Lee, W. H. et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91, 11733-11737 (1994).
50. INK4a promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63, 1596-1601 (2003).
51. Romanov, S. R. et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633-637 (2001).
52. INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84-88 (1998).
53. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793-797 (1999).
54. Esteller, M. et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60, 4366-4371 (2000).
55. Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366-381 (2003).
56. Wong, D. J., Foster, S. A., Galloway, D. A. & Reid, B. J. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol. Cell. Biol. 19, 5642-5651 (1999).
57. Bronner, C. E. et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368, 258-261 (1994).
58. Kane, M. F. et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808-811 (1997).
59. Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332-339 (1999).
60. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 61, 4689-4692 (2001).
61. Weinstein, I. B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002).
62. Gregorieff, A. & Clevers, H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 19, 877-890 (2005).
63. Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761-763 (1997).
64. Weinstein, I. B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21, 857-864 (2000).
65. Jen, J. et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54, 5523-5526 (1994).
66. DeAngelo, A. B., Geter, D. R., Rosenberg, D. W., Crary, C. K. & George, M. H. The induction of aberrant crypt foci (ACF) in the colons of rats by trihalomethanes administered in the drinking water. Cancer Lett. 187, 25-31 (2002).
67. Hao, X. P., Pretlow, T. G., Rao, J. S. & Pretlow, T. P. β-Catenin expression is altered in human colonic aberrant crypt foci. Cancer Res. 61, 8085-8088 (2001).
68. Mori, H., Yamada, Y., Kuno, T. & Hirose, Y. Aberrant crypt foci and β-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat. Res. 566, 191-208 (2004).
69. Papanikolaou, A., Wang, Q. S., Delker, D. A. & Rosenberg, D. W. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett. 130, 29-34 (1998).
70. Papanikolaou, A., Wang, Q. S., Papanikolaou, D., Whiteley, H. E. & Rosenberg, D. W. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21, 1567-1572 (2000).
71. Siu, I. M. et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res. 59, 63-66 (1999).
72. Yuan, P., Sun, M. H., Zhang, J. S., Zhu, X. Z. & Shi, D. R. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J. Gastroenterol. 7, 352-356 (2001).
73. Finch, P. W. et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl Acad. Sci. USA 94, 6770-6775 (1997).
74. Melkonyan, H. S. et al. SARPs: a family of secreted apoptosis-related proteins. Proc. Natl Acad. Sci. USA 94, 13636-13641 (1997).
75. Rattner, A. et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl Acad. Sci. USA 94, 2859-2863 (1997).
76. Taketo, M. M. Shutting down Wnt signal-activated cancer. Nature Genet. 36, 320-322 (2004).
77. Wales, M. M. et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med. 1, 570-577 (1995).
78. Guerardel, C. et al. Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J. Biol. Chem. 276, 3078-3089 (2001).
79. Fujii, H. et al. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 16, 2159-2164 (1998).
80. Carter, M. G. et al. Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum. Mol. Genet. 9, 413-419 (2000).
81. Chen, W. Y. et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature Genet. 33, 197-202 (2003).
82. Chen, W. et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6, 387-398 (2004).
83. Chen W. et al. Tumor suppressor HIC1 directly regulates SIRT1 and modulates p53-dependent apoptotic DNA damage responses. Cell 123, 437-448 (2005). Reports that the silencing of HIC1 in tumorigenesis might activate a network of events that lead to partial downregulation of p53 function and then to mutations in p53.
84. Frye, R. A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260, 273-279 (1999).
85. SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159 (2001).
86. Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383-2396 (2002).
87. Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137-148 (2001).
88. Hu, M. et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genet. 37, 899-905 (2005).
89. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
90. Tlsty, T. D. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97-104 (2001).
91. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
92. Issa, J. P., Kantarjian, H. M. & Kirkpatrick, P. Azacitidine. Nature Rev. Drug Discov. 4, 275-276 (2005).
93. Peters, A. H. et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol. Cell 12, 1577-1589 (2003).
94. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-1080 (2001).
95. Kouzarides, T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 12, 198-209 (2002).
96. Lund, A. H. & van Lohuizen, M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 16, 239-246 (2004).
97. Gasser, S. M. Positions of potential: nuclear organization and gene expression. Cell 104, 639-642 (2001).
98. Levine, S. S., King, I. F. & Kingston, R. E. Division of labor in polycomb group repression. Trends Biochem. Sci. 29, 478-485 (2004).
99. Ringrose, L. & Paro, R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu. Rev. Genet. 38, 413-443 (2004).
100. Valk-Lingbeek, M. E., Bruggeman, S. W. & van Lohuizen, M. Stem cells and cancer; the polycomb connection. Cell 118, 409-418 (2004).
101. Kuzmichev, A. et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl Acad. Sci. USA 102, 1859-1864 (2005).
102. Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315-2335 (2004).
103. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
104. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
105. Kirmizis, A., Bartley, S. M. & Farnham, P. J. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol. Cancer Ther. 2, 113-121 (2003).
106. Lessard, J. et al. Functional antagonism of the Polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13, 2691-2703 (1999).
107. Selker, E. U., Jensen, B. C. & Richardson, G. A. A portable signal causing faithful DNA methylation de novo in Neurospora crassa. Science 238, 48-53 (1987).
108. Tamaru, H. & Selker, E. U. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414, 277-283 (2001).
109. Tamaru, H. & Selker, E. U. Synthesis of signals for de novo DNA methylation in Neurospora crassa. Mol. Cell. Biol. 23, 2379-2394 (2003).
110. Bell, M. V. et al. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 64, 861-866 (1991).
111. Jackson, J. P., Lindroth, A. M., Cao, X. & Jacobsen, S. E. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 416, 556-560 (2002).
112. Johnson, L., Cao, X. & Jacobsen, S. Interplay between two epigenetic marks. DNA methylation and histone H3 lysine 9 methylation. Curr. Biol. 12, 1360-1367 (2002).
113. Cao, R. & Zhang, Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155-164 (2004).
114. Plath, K. et al. Role of histone H3 lysine 27 methylation in X inactivation. Science 300, 131-135 (2003).
115. Ayyanathan, K. et al. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev. 17, 1855-1869 (2003). A model of the evolution of the abnormal heritable transcriptional gene silencing that occurs during tumour progression.
116. Fahrner, J. A. & Baylin, S. B. Heterochromatin: stable and unstable invasions at home and abroad. Genes Dev. 17, 1805-1812 (2003).
117. Fahrner, J. A., Eguchi, S., Herman, J. G. & Baylin, S. B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62, 7213-7218 (2002).
118. Kondo, Y., Shen, L. & Issa, J. P. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol. 23, 206-215 (2003).
119. Nguyen, C. T. et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 62, 6456-6461 (2002).
120. Ghoshal, K. et al. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol. Cell. Biol. 22, 8302-8319 (2002).
121. Koizume, S., Tachibana, K., Sekiya, T., Hirohashi, S. & Shiraishi, M. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res. 30, 4770-4780 (2002).
122. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103-107 (1999).
123. Laird, P. W. The power and the promise of DNA methylation markers. Nature Rev. Cancer 3, 253-266 (2003).